Ascletis Pharma (SEHK:1672) At 5x P B On Obesity Trial Momentum Looks About Right

Ascletis Pharma (SEHK:1672) has drawn fresh attention after launching two Phase I obesity trials in the U.S. and starting a global Phase III program for its oral GLP-1 candidate ASC30.

See our latest analysis for Ascletis Pharma.

The recent obesity pipeline updates arrive after a mixed share price run for Ascletis Pharma. The stock rose 13.29% over a 7 day share price return but remains down 37.61% over a 90 day share price return and has recorded a 26.41% decline on the 1 year total shareholder return, suggesting that recent momentum is improving from a weaker medium term patch.

If this obesity news has you looking beyond a single stock, it could be a good moment to scan other health focused AI opportunities through the 131 healthcare AI stocks.

After a sharp 7 day rebound yet weaker returns over 3 and 12 months, the key issue for Ascletis Pharma now is simple: Has the recent obesity news already done the heavy lifting, or is meaningful upside still ahead as valuation is tested next?

Preferred Price-to-Book Multiple of 5x: Is It Justified for Ascletis Pharma?

With Ascletis Pharma last closing at HK$10.70, the key valuation reference point right now is its P/B ratio of 5x. That sits alongside mixed share price performance and an obesity pipeline that is still in early to mid stage trials.

The P/B ratio compares the company’s market value to its book value. For a biotech like Ascletis Pharma that is currently unprofitable and heavily focused on R&D, investors are often paying more for future potential than current earnings or revenue. A 5x P/B means the market is valuing the equity at five times the net assets on the balance sheet.

There are two contrasting signals here. On one side, Ascletis Pharma is described as good value when its 5x P/B is measured against a much higher peer average of 81.2x. On the other side, the same 5x P/B is classed as expensive relative to the Hong Kong Biotechs industry average of 3.6x. That suggests the stock trades at a premium to the broader local biotech group, while still sitting well below some higher multiple peers.

In simple terms, the market is assigning Ascletis Pharma a richer valuation than the average Hong Kong biotech but a much lower one than certain high multiple comparables. How investors weigh that gap will likely come down to conviction in the current obesity and broader pipeline, as well as views on profitability timing and future returns.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book ratio of 5x (ABOUT RIGHT relative to mixed peer comparisons)

However, the Ascletis Pharma story still faces real tests if obesity trials disappoint or if ongoing revenue and net income declines weigh on sentiment again.

Find out about the key risks to this Ascletis Pharma narrative.

Next Steps

Given the mixed tone around Ascletis Pharma’s valuation and obesity pipeline, it makes sense to check the underlying data yourself. You can then move quickly to form an independent view using the 3 important warning signs.

Looking for more investment ideas beyond Ascletis Pharma?

If Ascletis Pharma has caught your attention, now is a smart time to line up a few other ideas so you are not relying on a single stock story.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com